查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肉毒桿菌毒素市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)
市场调查报告书
商品编码
1190133

肉毒桿菌毒素市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Botulinum Toxin Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

肉毒桿菌毒素市场在基准年的价值为 46.5553 亿美元，预计在预测期内将以 9.5% 的复合年增长率增长。

主要亮点

  • COVID-19 在大流行期间对市场增长产生了重大影响。 这是由于更严格的坐月子规定的实施和美容手术等非择期手术的推迟导致肉毒桿菌毒素手术减少。 例如，根据美国整形外科学会发布的一份报告，2020 年将进行约 4,401,536 例微创 A 型肉毒桿菌毒素手术，比上一年进行的 A 型肉毒桿菌毒素手术减少 13%。
  • 手术数量的下降是由于 COVID-19 大流行导致世界各国政府实施了严格的规定，这对所研究的市场产生了重大影响。 然而，在大流行后放鬆对非选择性整容手术的严格指导方针后，整容手术的恢復预计将有助于未来五年的市场增长。
  • 目前有多种因素正在推动全球肉毒桿菌毒素市场的增长。 其中包括对整容手术的需求不断增加，扩大肉毒桿菌毒素治疗用途的研发计划不断增加，以及患者对非侵入性或微创治疗的偏好增加以及新产品开发。
  • 整容手术需求的增长预计将成为预测期内市场增长的主要驱动力。 美国整形外科医师学会在 2022 年进行的一项调查指出，美国 76% 的整形外科医生见证了整容手术的需求增加，23% 的人表示他们的业务翻了一番。 它还指出，A 型肉毒桿菌毒素将成为 2021 年至 2022 年期间患者最喜欢的微创整容手术之一。 预计对肉毒桿菌毒素治疗的需求增加将有助于预测期内的市场增长。
  • 此外，扩大肉毒桿菌毒素在各种非整容手术中的治疗用途，例如肌张力障碍、偏头痛等，预计也将有助于预测期内的市场增长。 此外，肉毒桿菌毒素可用作潜在疗法的各种疾病的流行预计将推动对肉毒桿菌毒素的需求，从而促进市场的增长。
  • 例如，AAN 于 2021 年 1 月发表的一篇论文指出，在美国的一项国际横断面队列研究中，肌张力障碍性震颤的患病率从 36.9% 到 48.4% 不等。 此外，越来越多的使用肉毒桿菌毒素治疗疾病的临床试验市场参与者预计将有助于市场增长。
  • 例如，2022 年 9 月，AEON Biopharma 报告了 ABP-450（prabotulinumtoxinA）6 治疗成人颈肌张力障碍的 2 期临床试验的良好顶线结果。 预计各种市场参与者的此类临床试验和产品开发将有助于预测期内的市场增长。
  • 此外，为满足对肉毒桿菌毒素不断增长的需求而推出的创新产品有望推动市场增长。 例如，2021 年 1 月，Maypharm 推出了肉毒桿菌毒素 METOX，可以抚平因日常面部活动引起的重度至中度皱纹，是一种有效的解决方案。
  • 因此，在预测期内，化妆品和非化妆品应用中对肉毒桿菌毒素的需求增加和产品频繁推出预计将推动市场增长。 然而，与肉毒桿菌毒素相关的副作用和缺乏支持整容手术的报销政策预计将在预测期内抑制市场增长。

主要市场趋势

预计在预测期内市场细分将占很大份额

  • 预计在预测期内，砾石线段将占据很大的市场份额。 A 型肉毒桿菌毒素可以改善砾石纹的外观，因为它是首选的非手术治疗方法。 A 型肉毒桿菌毒素是改善砾石纹外观的最优选的非手术治疗方法。 皱眉纹，也称为“十一”，是由于在听或读时皱眉、做鬼脸或註意力集中而导致的眉毛之间的垂直皱纹。 这些皱纹是由控制眉毛之间运动的肌肉的规律收缩引起的。 这种肌肉的反复收缩会导致皮肤失去弹性，产生深层皱纹，当肌肉放鬆时，这些皱纹也很明显。
  • 增加鼻唇沟的主要因素是衰老、强烈的阳光和精神压力。 肉毒桿菌毒素有望抑制此类皱纹的发生，并有助于市场的增长。
  • 用于处理砾石管线的产品发布和批准数量的增加预计会对市场产生积极影响。 例如，2022 年 9 月，美国食品和药物管理局 (USFDA) 批准了达西肉毒毒素 A-Ianm 注射液 (Daxxify)，用于暂时改善成人中度至重度砾石纹的外观。 同样，2022年6月，Galderma公布了前两项3期临床试验，显示Lilabotulinum Toxin A改善鼻唇沟，起效快，作用持续时间长达6个月，获得了一线结果。
  • 因此，在预测期内，对砾石纹治疗的需求增加以及可有效治疗砾石纹的肉毒桿菌毒素产品的推出等因素预计将促进肉毒桿菌毒素市场的增长。

预计在预测期内北美将占据很大的市场份额

  • 在预测期内，预计北美将主导全球市场。 预计在预测期内，对整容手术的需求不断增加、各种疾病的流行以及肉毒桿菌毒素治疗应用研究和开发活动的增加等主要因素将促进该地区的市场增长。
  • 例如，根据美国骨科医师学会 2020 年发布的一份报告，在美国的微创整容手术中，与男性相比，女性接受了大约 4,136,289 次肉毒桿菌毒素手术。超过 265,247 次肉毒桿菌毒素手术进行了治疗。
  • 此外，美国整形外科医师学会 (ASPS) 于 2022 年进行的一项调查显示，31-45 岁的患者最有可能想要使用 A 型肉毒桿菌毒素进行整容手术。 预计这种肉毒桿菌毒素治疗的采用率上升也将在预测期内推动市场增长的需求。
  • 此外，越来越多的化妆品和非化妆品应用的产品发布和产品批准有望促进市场增长。 例如，同样在 2022 年 3 月，Aquavit Pharmaceuticals, Inc 向食品和药物管理局提交了一项研究，以批准一种新的肉毒桿菌毒素药物 (DTX-021)。 DTX-021 是一种 A 型肉毒桿菌毒素製剂，用于治疗中度至重度灰色线。 同样，2021 年 4 月，Aquavit Holdings LLC 获得了在美国和加拿大註册、营销和商业化肉毒桿菌毒素（DTX-021）的独家许可。
  • 因此，美容程序需求不断增长、主要市场参与者的存在以及产品频繁发布等因素预计将促进该地区的市场增长。

竞争格局

由于存在多个市场参与者，肉毒桿菌毒素市场较为分散。 竞争格局包括对一些具有市场份额的国际和本地公司的分析。 市场参与者包括 Galderma、Evolus, Inc.、Merz Pharma GmbH & Co. KGaA、AbbVie Inc.（Allergan）和 Ipsen Pharma。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 对整容手术的需求增加
    • 加强研发计划以扩大肉毒桿菌毒素的治疗用途
  • 市场製约因素
    • 与肉毒桿菌毒素相关的副作用
    • 缺乏支持美容治疗的报销政策
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模 - 百万美元）

  • 通过使用
    • 化妆品用途
      • 砾石线
      • 外眼线（鱼尾纹）
      • 额头皱纹
      • 其他美容用途
    • 非美容应用
      • 肌张力障碍
      • 慢性偏头痛
      • 眼科疾病
      • 其他非化妆品应用
  • 最终用户
    • 水疗/美容中心
    • 诊所和医院
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Merz Pharma GmbH & Co. KGaA
    • AbbVie Inc.（Allergan）
    • Evolus, Inc.
    • Revance Therapeutics Inc.
    • HUGEL, Inc.
    • Ipsen Pharma
    • US WorldMeds LLC
    • Medytox
    • Eisai
    • Hugh Source International
    • Galderma
    • Daewoong Pharmaceuticals

第七章市场机会与未来趋势

简介目录
Product Code: 67009

The botulinum toxin market was valued at USD 4,655.53 million in the base year, and it is expected to register a CAGR of 9.5% during the forecast period.

Key Highlights

  • COVID-19 had a significant impact on the growth of the market during the pandemic period. This was due to the reduction of botulinum toxin procedures due to the imposition of strict lockdown restrictions and the postponement of non-elective surgeries such as cosmetic surgeries. For instance, according to the report published in the American Society of Plastic Surgeons, around 4,401,536 Botulinum Toxin Type A minimally-invasive procedures were performed in 2020, a 13% decrease from the Botulinum Toxin Type A procedures performed in the previous year.
  • The decline in the number of surgeries was due to the strict regulations imposed by governments across different countries due to the COVID-19 pandemic, which highly affected the studied market. However, the resumption of cosmetic surgeries after the relaxation of strict guidelines on non-elective aesthetic procedures during the post-pandemic situations is expected to contribute to the market's growth over the coming five years.
  • Various factors are currently driving the growth of the global botulinum toxin market. These include the increasing demand for aesthetic procedures, growing research and development initiatives to expand the therapeutic applications of botulinum toxin, and growing patient preference for non-invasive or minimal treatments coupled with novel product development.
  • The increasing demand for aesthetic procedures is expected to be the major driver for the market's growth over the forecast period. The survey conducted by the American Society of Plastic Surgeons in 2022 mentioned that in United States, 76% of plastic surgeons witnessed increased demand for cosmetic procedures and 23% reported that their business has doubled. The report also mentioned that Botulinum Toxin Type A is one of the top minimally invasive cosmetic procedures among patients during 2021-2022. Such increasing demand for botulinum toxin procedures is expected to contribute to the market's growth over the forecast period.
  • Also, growing applications for the therapeutic usage of botulinum toxin in various non-cosmetic procedures such as dystonia, migraine, and others are expected to contribute to the growth of the market over the forecast period. Moreover, the prevalence of various disorders in which the botulinum toxin can be used as the potential therapy is expected to drive the demand for the botulinum toxin, thereby contributing to the market's growth.
  • For instance, an article published by AAN in January 2021 mentioned that the prevalence of dystonia tremor in the international cross-sectional cohort study varied from 36.9% to 48.4% in United States. Also, the increasing clinical trials market player for treating diseases using botulinum toxin is expected to contribute to the market's growth.
  • For instance, in September 2022, AEON Biopharma reported positive topline results from the phase-2 clinical trial of ABP-450 (prabotulinumtoxinA) in 6treatment of cervical dystonia in adults. Such clinical trials and product development activities by various market players are expected to contribute to the market's growth over the forecast period.
  • Furthermore, innovative product launches to meet the growing demand for botulinum toxin are expected to boost the market's growth. For instance, in January 2021, Maypharm launched a botulinum toxin, METOX, which is an effective solution for smoothing any wrinkles from severe to moderate caused by daily active facial movements.
  • Thus, the increasing demand for botulinum toxin in cosmetic and non-cosmetic applications and frequent product launches are expected to drive the market's growth over the forecast period. However, adverse effects associated with botulinum toxin and the lack of reimbursement policies supporting cosmetic procedures are expected to restrain the market's growth over the forecast period.

Key Market Trends

Glabellar Lines Segment is Expected to Hold Significant Share in the Market Over the Forecast Period

  • The glabellar lines segment is expected to hold a significant market share over the forecast period. The botulinum toxin- A is the most preferred non-surgical treatment to improve the appearance of glabellar lines. The glabellar lines, also called the 'eleven', are the vertical lines that develop between the eyebrows due to frowning, scowling, or merely focusing while listening or reading. These lines occur due to regular and repeated muscle contractions that control the movement between the eyebrows. These repeated movements cause a loss of skin elasticity, resulting in the formation of deep wrinkles, which can even be seen when the muscle is relaxed.
  • The major factors leading to increased glabellar lines are natural aging, exposure to harsh sunlight, and mental stress. Such occurrences of glabellar lines are expected to contribute to the demand for botulinum toxin, thereby contributing to market growth.
  • The increasing launch of products and approvals for treating glabellar lines is expected to impact the market positively. For instance, in September 2022, United States Food and Drug Administration (USFDA) approved daxibotulinumtoxinA-Ianm injection (Daxxify) to temporarily improve the appearance of moderate to severe glabellar lines in adults. Similarly, in June 2022, Galderma obtained topline results from two phase-3 clinical studies demonstrating that RelabotulinumtoxinA improves glabellar lines with a rapid onset of action and a long duration of up to six months.
  • Thus, the factors such as rising demand for the treatment of glabellar lines and the launch of effective botulinum toxin products for the treatment of glabellar lines are expected to contribute to the growth of the botulinum toxin market during the forecast period.

North America is Expected to Hold Significant Share in the Market Over the Forecast Period

  • North America is expected to dominate the global market over the forecast period. The major factors such as rising demand for aesthetic procedures, the prevalence of various disorders, and growing research and development activities for the therapeutic applications of botulinum toxin are expected to contribute to the growth of the market over the forecast period in this region.
  • For instance, according to the report published in the American Society of Plastic Surgeons in 2020, among cosmetic minimally-invasive procedures, there were around 4,136,289 botulinum toxin procedures performed on females and over 265,247 botulinum toxin procedures performed on males in United States.
  • Similarly, a survey conducted by the American Society of Plastic Surgeons (ASPS) in 2022 revealed that patients aged 31- 45 years most commonly seek botulinum toxin type A cosmetic procedures. Such rising adoption of botulinum toxin procedures is also expected to drive the demand for the growth of the market over the forecast period.
  • Additionally, the increasing product launches and product approvals for cosmetic and non-cosmetic applications are expected to contribute to the growth of the market. For instance, Also, in March 2022, Aquavit Pharmaceuticals, Inc submitted its investigation of a New drug for botulinum toxin (DTX-021) to the Food and Administration for approval. The DTX-021 is a botulinum toxin type A drug intended for the treatment of moderate to severe glabellar lines. Similarly, in April 2021, Aquavit Holdings LLC acquired an exclusive license to register, market, and commercialize a botulinum toxin (DTX-021) in United States and Canada.
  • Hence, the factors such as rising demand for aesthetic procedures, the presence of major market players, and frequent product launches are expected to contribute to the growth of the market in this region.

Competitive Landscape

The botulinum toxin market is moderately fragmented in nature due to the presence of several market players. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares. Major companies in the market are Galderma, Evolus, Inc., Merz Pharma GmbH & Co. KGaA, AbbVie Inc. (Allergan), and Ipsen Pharma, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand for Aesthetic Procedures
    • 4.2.2 Growing Research and Development Initiatives to Expand the Therapeutic Applications of Botulinum Toxin
  • 4.3 Market Restraints
    • 4.3.1 Adverse effects Associated with Botulinum Toxin
    • 4.3.2 Lack of Reimbursement Policies Supporting Cosmetic Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Application
    • 5.1.1 Cosmetic Applications
      • 5.1.1.1 Glabellar lines
      • 5.1.1.2 Lateral canthal lines (crow's feet)
      • 5.1.1.3 Forehead Lines
      • 5.1.1.4 Other Cosmetic Applications​
    • 5.1.2 Non-Cosmetic Applications
      • 5.1.2.1 Dystonia
      • 5.1.2.2 Chronic migraine
      • 5.1.2.3 Ophthalmologic disorders
      • 5.1.2.4 Other Non-cosmetic Applications
  • 5.2 By End User
    • 5.2.1 Spas and Beauty Centers
    • 5.2.2 Clinics and Hospitals
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merz Pharma GmbH & Co. KGaA
    • 6.1.2 AbbVie Inc. (Allergan)
    • 6.1.3 Evolus, Inc.
    • 6.1.4 Revance Therapeutics Inc.
    • 6.1.5 HUGEL, Inc.
    • 6.1.6 Ipsen Pharma
    • 6.1.7 US WorldMeds LLC
    • 6.1.8 Medytox
    • 6.1.9 Eisai
    • 6.1.10 Hugh Source International
    • 6.1.11 Galderma
    • 6.1.12 Daewoong Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS